Literature DB >> 33706808

A meta-analysis of the epidemiology of giant cell arteritis across time and space.

Katherine J Li1, Daniel Semenov1, Matthew Turk2, Janet Pope3.   

Abstract

INTRODUCTION: Giant cell arteritis (GCA) is a common large vessel vasculitis in those over age 50 years. This meta-analysis examined the geographical and temporal distribution of the incidence, prevalence, and mortality of GCA.
METHODS: A systematic review was conducted using EMBASE, Scopus, and PubMed from their inceptions until 2019. Studies were included if they reported at least 50 or more GCA patients and defined the location and time frame. Articles on mortality were included and standardized mortality ratio (SMR) was extracted where possible. Mean pooled prevalence, incidence, and SMR were calculated using a random effects model. Linear regression was used to explore correlations between latitude and incidence, prevalence, and mortality.
RESULTS: Of the 3569 citations identified, 107 were included. The pooled incidence of GCA was 10.00 [9.22, 10.78] cases per 100,000 people over 50 years old. This incidence was highest in Scandinavia 21.57 [18.90, 24.23], followed by North and South America 10.89 [8.78, 13.00], Europe 7.26 [6.05, 8.47], and Oceania 7.85 [- 1.48, 17.19]. Pooled prevalence was 51.74 [42.04, 61.43] cases per 100,000 people over age 50. Annual mortality was 20.44 [17.84, 23.03] deaths/1000. Mortality generally decreased over the years of publication (p = 0.0008). Latitude correlated significantly with incidence (p = 0.0011), but not with prevalence, or mortality.
CONCLUSIONS: GCA incidence varies nearly 3-fold between regions and is highest in Scandinavia but not significantly. Mortality may be improving over time.

Entities:  

Keywords:  Epidemiology; GCA; Geographic variation; Giant cell arteritis; Incidence; Meta-analysis; Mortality; Prevalence; Temporal arteritis; Temporal trend

Mesh:

Year:  2021        PMID: 33706808      PMCID: PMC7948334          DOI: 10.1186/s13075-021-02450-w

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  17 in total

Review 1.  Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment.

Authors:  E Nordborg; C Nordborg
Journal:  Rheumatology (Oxford)       Date:  2003-03       Impact factor: 7.580

Review 2.  The geo-epidemiology of temporal (giant cell) arteritis.

Authors:  Jennifer L Lee; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

3.  Increase in age at onset of giant cell arteritis: a population-based study.

Authors:  Tanaz A Kermani; Valentin S Schäfer; Cynthia S Crowson; Gene G Hunder; Sherine E Gabriel; Eric L Matteson; Kenneth J Warrington
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103

4.  Increased Incidence of Giant Cell Arteritis in Urban Areas?

Authors:  Lene Kristin Brekke; Bjørg-Tilde Fevang; Geirmund Myklebust
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

5.  Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study.

Authors:  Miguel A Gonzalez-Gay; Jose A Miranda-Filloy; Maria J Lopez-Diaz; Roberto Perez-Alvarez; Carlos Gonzalez-Juanatey; Amalia Sanchez-Andrade; Javier Martin; Javier Llorca
Journal:  Medicine (Baltimore)       Date:  2007-03       Impact factor: 1.889

6.  Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.

Authors:  Rogelio J Palomino-Morales; Tomas R Vazquez-Rodriguez; Orlando Torres; Inmaculada C Morado; Santos Castañeda; Jose A Miranda-Filloy; Jose L Callejas-Rubio; Benjamin Fernandez-Gutierrez; Miguel A Gonzalez-Gay; Javier Martin
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

Review 7.  Temporal trends in the incidence of multiple sclerosis: a systematic review.

Authors:  Alvaro Alonso; Miguel A Hernán
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

8.  Giant cell arteritis and mortality.

Authors:  R Wade Crow; Bradley J Katz; Judith E A Warner; Stephen C Alder; Kang Zhang; Susan Schulman; Kathleen B Digre
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-04       Impact factor: 6.053

Review 9.  Giant cell arteritis: early diagnosis is key.

Authors:  Iyza F Baig; Alexis R Pascoe; Ashwini Kini; Andrew G Lee
Journal:  Eye Brain       Date:  2019-01-17

10.  Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation.

Authors:  Sarah Louise Mackie; John C Taylor; Lubna Haroon-Rashid; Stephen Martin; Bhaskar Dasgupta; Andrew Gough; Michael Green; Lesley Hordon; Stephen Jarrett; Colin T Pease; Jennifer H Barrett; Richard Watts; Ann W Morgan
Journal:  Arthritis Res Ther       Date:  2015-07-30       Impact factor: 5.156

View more
  13 in total

1.  Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort.

Authors:  Thomas D Garvey; Matthew J Koster; Cynthia S Crowson; Kenneth J Warrington
Journal:  Semin Arthritis Rheum       Date:  2021-09-27       Impact factor: 5.532

2.  Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).

Authors:  Solange Gonzalez Chiappe; Sarah Lechtman; Carla Soledad Maldini; Arsène Mekinian; Thomas Papo; Thomas Sené; Alfred Daniel Mahr
Journal:  Rheumatol Int       Date:  2022-07-12       Impact factor: 3.580

Review 3.  Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

Authors:  Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy
Journal:  Front Med (Lausanne)       Date:  2022-06-06

4.  An update on the clinical approach to giant cell arteritis.

Authors:  Rachel Piccus; Michael Stormly Hansen; Steffen Hamann; Susan P Mollan
Journal:  Clin Med (Lond)       Date:  2022-03       Impact factor: 5.410

Review 5.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

6.  Pericardial effusion in giant cell arteritis is associated with increased inflammatory markers: a retrospective cohort study.

Authors:  Quentin Gomes de Pinho; Aurélie Daumas; Audrey Benyamine; Julien Bertolino; Pascal Rossi; Nicolas Schleinitz; Jean-Robert Harlé; Pierre André Jarrot; Gilles Kaplanski; Julie Berbis; Brigitte Granel
Journal:  Rheumatol Int       Date:  2022-05-07       Impact factor: 3.580

7.  Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway.

Authors:  Marieke van Nieuwland; Elisabeth Brouwer; Lize M Neuman; Lenny van Bon; Celina Alves
Journal:  Rheumatol Adv Pract       Date:  2022-05-19

Review 8.  Looking ahead: giant-cell arteritis in 10 years time.

Authors:  Milena Bond; Alessandro Tomelleri; Frank Buttgereit; Eric L Matteson; Christian Dejaco
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625

Review 9.  Global epidemiology of vasculitis.

Authors:  Richard A Watts; Gulen Hatemi; Jane C Burns; Aladdin J Mohammad
Journal:  Nat Rev Rheumatol       Date:  2021-12-01       Impact factor: 20.543

10.  Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup.

Authors:  Owen Cronin; Hannah Preston; Heba Fahmy; Barbara Kuske; Malinder Singh; Naomi Scott; Sean Kerrigan; Lucy Moran; John Harvie; Helen Harris; Barbara Hauser; Neil D McKay
Journal:  Rheumatol Adv Pract       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.